Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma
To assess the place of passive immunotherapy in the treatment of AIDS, a randomized study was conducted that evaluated the safety and short-term efficacy of serial transfusions of human immunodeficiency virus type 1 (HIV-1) seropositive plasma in 18 patients. Heat-inactivated anti-HIV antibody-rich...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1992-02, Vol.165 (2), p.364-368 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368 |
|---|---|
| container_issue | 2 |
| container_start_page | 364 |
| container_title | The Journal of infectious diseases |
| container_volume | 165 |
| creator | Vittecoq, D. Mattlinger, B. Barre-Sinoussi, F. Courouce, A.M. Rouzioux, C. Doinel, C. Bary, M. Viard, J.P. Bach, J.F. Rouger, P. Lefrere, J.J. |
| description | To assess the place of passive immunotherapy in the treatment of AIDS, a randomized study was conducted that evaluated the safety and short-term efficacy of serial transfusions of human immunodeficiency virus type 1 (HIV-1) seropositive plasma in 18 patients. Heat-inactivated anti-HIV antibody-rich plasma was compared with seronegative fresh-frozen seronegative plasma given in addition to zidovudine and other conventional prophylactic treatments. Seven transfusions every 2 weeks ofimmune plasma significantly reduced (2 vs. 8, P = .016) the number of opportunistic infections. Antigenemia became undetectable. When transfusions were stopped, positive p24 antigenemia returned at a level higher than before treatment and was correlated with a severe clinical deterioration, suggesting a rebound effect. This trial suggests that passive immunotherapy is promising in AIDS treatment. It confirms also that plasma donation does not affect donors' CD4 cell count over a 1-year period. In patients with severe immunodeficiency, special attention should be paid to withdrawal of an effective therapy as virologic relapse may be explosive and poorly tolerated. |
| doi_str_mv | 10.1093/infdis/165.2.364 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_72789236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30112547</jstor_id><sourcerecordid>30112547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-cbaf38de1736849d767d32bcae43e046390785d85ba0976e24cf42b5894e2d3c3</originalsourceid><addsrcrecordid>eNqFkU9v0zAYxiMEGmVw54LkA-KWzv8dc6sGo5UmUW1lmnqxHNthHk3S-U0mykfj05EuZTtw4GRLz_P83td-suwtwVOCNTuJTeUjnBAppnTKJH-WTYhgKpeSsOfZBGNKc1Jo_TJ7BXCLMeZMqqPsiCiGNaaT7PfSAsT7gBZ13TdtdxOS3e5QbNBs8enyI5qhC9v4to6_gkerFO0GtRW6DA-3eV_b5pD0oYouhsbt0FVMPeTLFmK3J6-SbaDqIbYN7MPLjYXaoovobvZztpSjWdPFsvUxALoPCXr4JzRMbJvw3T4QR8Lr7EVlNxDeHM7j7NvZ59XpPD__-mVxOjvPHSe8y11pK1b4MDxZFlx7JZVntHQ2cBYwl0xjVQhfiNJirWSg3FWclqLQPFDPHDvOPozcbWrv-gCdqSO4sNnYJrQ9GEVVoSmT_zUSSQjVigxGPBpdagFSqMw2xdqmnSHY7Hs1Y69DQhhqhl6HyLsDuy_r4J8CY5GD_v6gW3B2Uw3f5wbAX5vgRFIhnjC30LXpUWZ42ExwNej5qEfows9H3aYfRiqmhJlfr836an2mr-nKzNkfDQbIVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16112971</pqid></control><display><type>article</type><title>Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma</title><source>MEDLINE</source><source>JSTOR</source><creator>Vittecoq, D. ; Mattlinger, B. ; Barre-Sinoussi, F. ; Courouce, A.M. ; Rouzioux, C. ; Doinel, C. ; Bary, M. ; Viard, J.P. ; Bach, J.F. ; Rouger, P. ; Lefrere, J.J.</creator><creatorcontrib>Vittecoq, D. ; Mattlinger, B. ; Barre-Sinoussi, F. ; Courouce, A.M. ; Rouzioux, C. ; Doinel, C. ; Bary, M. ; Viard, J.P. ; Bach, J.F. ; Rouger, P. ; Lefrere, J.J.</creatorcontrib><description>To assess the place of passive immunotherapy in the treatment of AIDS, a randomized study was conducted that evaluated the safety and short-term efficacy of serial transfusions of human immunodeficiency virus type 1 (HIV-1) seropositive plasma in 18 patients. Heat-inactivated anti-HIV antibody-rich plasma was compared with seronegative fresh-frozen seronegative plasma given in addition to zidovudine and other conventional prophylactic treatments. Seven transfusions every 2 weeks ofimmune plasma significantly reduced (2 vs. 8, P = .016) the number of opportunistic infections. Antigenemia became undetectable. When transfusions were stopped, positive p24 antigenemia returned at a level higher than before treatment and was correlated with a severe clinical deterioration, suggesting a rebound effect. This trial suggests that passive immunotherapy is promising in AIDS treatment. It confirms also that plasma donation does not affect donors' CD4 cell count over a 1-year period. In patients with severe immunodeficiency, special attention should be paid to withdrawal of an effective therapy as virologic relapse may be explosive and poorly tolerated.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/165.2.364</identifier><identifier>PMID: 1730902</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acquired Immunodeficiency Syndrome - therapy ; AIDS ; AIDS/HIV ; Antibodies ; Biological and medical sciences ; Blood donation ; Blood plasma ; Blood Transfusion ; Blotting, Western ; Concise Communications ; HIV ; HIV 1 ; HIV Antibodies - therapeutic use ; HIV Antigens - blood ; HIV Core Protein p24 - immunology ; Humans ; Immunization, Passive ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infections ; Medical sciences ; Opportunistic infections ; Opportunistic Infections - prevention & control ; Plasma - immunology ; Viruses</subject><ispartof>The Journal of infectious diseases, 1992-02, Vol.165 (2), p.364-368</ispartof><rights>Copyright 1992 The University of Chicago</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-cbaf38de1736849d767d32bcae43e046390785d85ba0976e24cf42b5894e2d3c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30112547$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30112547$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27923,27924,58016,58249</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5416255$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1730902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vittecoq, D.</creatorcontrib><creatorcontrib>Mattlinger, B.</creatorcontrib><creatorcontrib>Barre-Sinoussi, F.</creatorcontrib><creatorcontrib>Courouce, A.M.</creatorcontrib><creatorcontrib>Rouzioux, C.</creatorcontrib><creatorcontrib>Doinel, C.</creatorcontrib><creatorcontrib>Bary, M.</creatorcontrib><creatorcontrib>Viard, J.P.</creatorcontrib><creatorcontrib>Bach, J.F.</creatorcontrib><creatorcontrib>Rouger, P.</creatorcontrib><creatorcontrib>Lefrere, J.J.</creatorcontrib><title>Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>To assess the place of passive immunotherapy in the treatment of AIDS, a randomized study was conducted that evaluated the safety and short-term efficacy of serial transfusions of human immunodeficiency virus type 1 (HIV-1) seropositive plasma in 18 patients. Heat-inactivated anti-HIV antibody-rich plasma was compared with seronegative fresh-frozen seronegative plasma given in addition to zidovudine and other conventional prophylactic treatments. Seven transfusions every 2 weeks ofimmune plasma significantly reduced (2 vs. 8, P = .016) the number of opportunistic infections. Antigenemia became undetectable. When transfusions were stopped, positive p24 antigenemia returned at a level higher than before treatment and was correlated with a severe clinical deterioration, suggesting a rebound effect. This trial suggests that passive immunotherapy is promising in AIDS treatment. It confirms also that plasma donation does not affect donors' CD4 cell count over a 1-year period. In patients with severe immunodeficiency, special attention should be paid to withdrawal of an effective therapy as virologic relapse may be explosive and poorly tolerated.</description><subject>Acquired Immunodeficiency Syndrome - therapy</subject><subject>AIDS</subject><subject>AIDS/HIV</subject><subject>Antibodies</subject><subject>Biological and medical sciences</subject><subject>Blood donation</subject><subject>Blood plasma</subject><subject>Blood Transfusion</subject><subject>Blotting, Western</subject><subject>Concise Communications</subject><subject>HIV</subject><subject>HIV 1</subject><subject>HIV Antibodies - therapeutic use</subject><subject>HIV Antigens - blood</subject><subject>HIV Core Protein p24 - immunology</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infections</subject><subject>Medical sciences</subject><subject>Opportunistic infections</subject><subject>Opportunistic Infections - prevention & control</subject><subject>Plasma - immunology</subject><subject>Viruses</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v0zAYxiMEGmVw54LkA-KWzv8dc6sGo5UmUW1lmnqxHNthHk3S-U0mykfj05EuZTtw4GRLz_P83td-suwtwVOCNTuJTeUjnBAppnTKJH-WTYhgKpeSsOfZBGNKc1Jo_TJ7BXCLMeZMqqPsiCiGNaaT7PfSAsT7gBZ13TdtdxOS3e5QbNBs8enyI5qhC9v4to6_gkerFO0GtRW6DA-3eV_b5pD0oYouhsbt0FVMPeTLFmK3J6-SbaDqIbYN7MPLjYXaoovobvZztpSjWdPFsvUxALoPCXr4JzRMbJvw3T4QR8Lr7EVlNxDeHM7j7NvZ59XpPD__-mVxOjvPHSe8y11pK1b4MDxZFlx7JZVntHQ2cBYwl0xjVQhfiNJirWSg3FWclqLQPFDPHDvOPozcbWrv-gCdqSO4sNnYJrQ9GEVVoSmT_zUSSQjVigxGPBpdagFSqMw2xdqmnSHY7Hs1Y69DQhhqhl6HyLsDuy_r4J8CY5GD_v6gW3B2Uw3f5wbAX5vgRFIhnjC30LXpUWZ42ExwNej5qEfows9H3aYfRiqmhJlfr836an2mr-nKzNkfDQbIVw</recordid><startdate>19920201</startdate><enddate>19920201</enddate><creator>Vittecoq, D.</creator><creator>Mattlinger, B.</creator><creator>Barre-Sinoussi, F.</creator><creator>Courouce, A.M.</creator><creator>Rouzioux, C.</creator><creator>Doinel, C.</creator><creator>Bary, M.</creator><creator>Viard, J.P.</creator><creator>Bach, J.F.</creator><creator>Rouger, P.</creator><creator>Lefrere, J.J.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19920201</creationdate><title>Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma</title><author>Vittecoq, D. ; Mattlinger, B. ; Barre-Sinoussi, F. ; Courouce, A.M. ; Rouzioux, C. ; Doinel, C. ; Bary, M. ; Viard, J.P. ; Bach, J.F. ; Rouger, P. ; Lefrere, J.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-cbaf38de1736849d767d32bcae43e046390785d85ba0976e24cf42b5894e2d3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Acquired Immunodeficiency Syndrome - therapy</topic><topic>AIDS</topic><topic>AIDS/HIV</topic><topic>Antibodies</topic><topic>Biological and medical sciences</topic><topic>Blood donation</topic><topic>Blood plasma</topic><topic>Blood Transfusion</topic><topic>Blotting, Western</topic><topic>Concise Communications</topic><topic>HIV</topic><topic>HIV 1</topic><topic>HIV Antibodies - therapeutic use</topic><topic>HIV Antigens - blood</topic><topic>HIV Core Protein p24 - immunology</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infections</topic><topic>Medical sciences</topic><topic>Opportunistic infections</topic><topic>Opportunistic Infections - prevention & control</topic><topic>Plasma - immunology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vittecoq, D.</creatorcontrib><creatorcontrib>Mattlinger, B.</creatorcontrib><creatorcontrib>Barre-Sinoussi, F.</creatorcontrib><creatorcontrib>Courouce, A.M.</creatorcontrib><creatorcontrib>Rouzioux, C.</creatorcontrib><creatorcontrib>Doinel, C.</creatorcontrib><creatorcontrib>Bary, M.</creatorcontrib><creatorcontrib>Viard, J.P.</creatorcontrib><creatorcontrib>Bach, J.F.</creatorcontrib><creatorcontrib>Rouger, P.</creatorcontrib><creatorcontrib>Lefrere, J.J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vittecoq, D.</au><au>Mattlinger, B.</au><au>Barre-Sinoussi, F.</au><au>Courouce, A.M.</au><au>Rouzioux, C.</au><au>Doinel, C.</au><au>Bary, M.</au><au>Viard, J.P.</au><au>Bach, J.F.</au><au>Rouger, P.</au><au>Lefrere, J.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1992-02-01</date><risdate>1992</risdate><volume>165</volume><issue>2</issue><spage>364</spage><epage>368</epage><pages>364-368</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>To assess the place of passive immunotherapy in the treatment of AIDS, a randomized study was conducted that evaluated the safety and short-term efficacy of serial transfusions of human immunodeficiency virus type 1 (HIV-1) seropositive plasma in 18 patients. Heat-inactivated anti-HIV antibody-rich plasma was compared with seronegative fresh-frozen seronegative plasma given in addition to zidovudine and other conventional prophylactic treatments. Seven transfusions every 2 weeks ofimmune plasma significantly reduced (2 vs. 8, P = .016) the number of opportunistic infections. Antigenemia became undetectable. When transfusions were stopped, positive p24 antigenemia returned at a level higher than before treatment and was correlated with a severe clinical deterioration, suggesting a rebound effect. This trial suggests that passive immunotherapy is promising in AIDS treatment. It confirms also that plasma donation does not affect donors' CD4 cell count over a 1-year period. In patients with severe immunodeficiency, special attention should be paid to withdrawal of an effective therapy as virologic relapse may be explosive and poorly tolerated.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>1730902</pmid><doi>10.1093/infdis/165.2.364</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1992-02, Vol.165 (2), p.364-368 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72789236 |
| source | MEDLINE; JSTOR |
| subjects | Acquired Immunodeficiency Syndrome - therapy AIDS AIDS/HIV Antibodies Biological and medical sciences Blood donation Blood plasma Blood Transfusion Blotting, Western Concise Communications HIV HIV 1 HIV Antibodies - therapeutic use HIV Antigens - blood HIV Core Protein p24 - immunology Humans Immunization, Passive Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infections Medical sciences Opportunistic infections Opportunistic Infections - prevention & control Plasma - immunology Viruses |
| title | Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A34%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Passive%20Immunotherapy%20in%20AIDS:%20A%20Randomized%20Trial%20of%20Serial%20Human%20Immunodeficiency%20Virus-Positive%20Transfusions%20of%20Plasma%20Rich%20in%20p24%20Antibodies%20versus%20Transfusions%20of%20Seronegative%20Plasma&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Vittecoq,%20D.&rft.date=1992-02-01&rft.volume=165&rft.issue=2&rft.spage=364&rft.epage=368&rft.pages=364-368&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/165.2.364&rft_dat=%3Cjstor_proqu%3E30112547%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16112971&rft_id=info:pmid/1730902&rft_jstor_id=30112547&rfr_iscdi=true |